KYTHERA Biopharmaceuticals Presents Positive MRI Results from Phase IIb Study of ATX-101 in Reduction of Double Chin

By: Benzinga
KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH ) today presented positive results that found MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat (SMF),
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.